0639 GMT - Fresenius Medical Care's results should see a positive share-price response on a higher net profit and sales and earnings that topped views, Morgan Stanley analysts say in a note. The German dialysis company's sales and earnings beat was driven by higher demand for is care enablement segment and cost discipline, they say. The company's reiterated full-year outlook for revenue and operating profit and a stable U.S. market treatment growth is a positive, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 02:42 ET (06:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.